Your browser doesn't support javascript.
loading
Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings.
Smith, D Max; Peshkin, Beth N; Springfield, T Blaise; Brown, Ryan P; Hwang, Elizabeth; Kmiecik, Susanna; Shapiro, Richard; Eldadah, Zayd; Lundergan, Conor; McAlduff, Joel; Levin, Bonnie; Swain, Sandra M.
Afiliación
  • Smith DM; MedStar Health, Columbia, Maryland, USA.
  • Peshkin BN; Georgetown University Medical Center, Washington, DC, USA.
  • Springfield TB; Georgetown University Medical Center, Washington, DC, USA.
  • Brown RP; Georgetown University Medical Center, Washington, DC, USA.
  • Hwang E; MedStar Health, Columbia, Maryland, USA.
  • Kmiecik S; MedStar Health, Columbia, Maryland, USA.
  • Shapiro R; MedStar Georgetown University Hospital, Washington, DC, USA.
  • Eldadah Z; MedStar Union Memorial Hospital, Baltimore, Maryland, USA.
  • Lundergan C; MedStar Washington Hospital Center, Washington, DC, USA.
  • McAlduff J; MedStar Cardiology Associates, LLC, Leonardtown, Maryland, USA.
  • Levin B; MedStar Health, Columbia, Maryland, USA.
  • Swain SM; MedStar Health, Columbia, Maryland, USA.
Clin Transl Sci ; 13(3): 618-627, 2020 05.
Article en En | MEDLINE | ID: mdl-31961467
ABSTRACT
Most literature describing pharmacogenetic implementations are within academic medical centers and use single-gene tests. Our objective was to describe the results and lessons learned from a multisite pharmacogenetic pilot that utilized panel-based testing in academic and nonacademic settings. This was a retrospective analysis of 667 patients from a pilot in 4 perioperative and 5 outpatient cardiology clinics. Recommendations related to 12 genes and 65 drugs were classified as actionable or not actionable. They were ascertained from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and US Food and Drug Administration (FDA) labeling. Patients displayed a high prevalence of actionable results (88%, 99%) and use of medications (28%, 46%) with FDA or CPIC recommendations, respectively. Sixteen percent of patients had an actionable result for a current medication per CPIC compared with 5% per FDA labeling. A systematic approach by a health system may be beneficial given the quantity and diversity of patients affected.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pautas de la Práctica en Medicina / Atención Perioperativa / Medicina de Precisión / Atención Ambulatoria / Pruebas de Farmacogenómica Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Clin Transl Sci Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pautas de la Práctica en Medicina / Atención Perioperativa / Medicina de Precisión / Atención Ambulatoria / Pruebas de Farmacogenómica Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Clin Transl Sci Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos